COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin / Cascinu, S; Scartozzi, M; Carbonari, G; Pierantoni, C; Verdecchia, L; Mariani, C; Squadroni, M; Antognoli, S; Silva, Rr; Giampieri, Riccardo; Berardi, Rossana. - In: AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS. - ISSN 0277-3732. - Oct 2007:(2007), pp. 526-530.
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin
GIAMPIERI, RICCARDO;BERARDI, ROSSANA
2007-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
